dr. chris vinnard's 2013 hiv treatment update
TRANSCRIPT
![Page 1: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/1.jpg)
HIV Treatment Update 2013:
What’s new?
Christopher Vinnard, MD MPH MSCEAssistant Professor of MedicineDivision of Infectious Diseases & HIV MedicineDrexel University College of Medicine
![Page 2: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/2.jpg)
A new report of a cure...
![Page 3: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/3.jpg)
![Page 4: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/4.jpg)
![Page 5: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/5.jpg)
Functional HIV Cure after Very Early ART of an Infected Infant Infant exposure to HIV was confirmed through
review of maternal HIV antibody and plasma viral load testing
Infant infection was documented by plasma viral load testing
ART (Combivir + Nevirapine) initiated in the infant at 30 hours of age
Persistence of HIV following treatment discontinuation was assessed using plasma viral load, proviral DNA, and HIV antibody testing
Ultrasensitive assays done at age 24 and 26 months
CROI 2013
![Page 6: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/6.jpg)
Results
Infant infection was confirmed by positive HIV DNA and RNA testing on 2 separate blood samples obtained on 2nd day of life
3 additional plasma viral load tests on day 7, 12, and 20 were positive, before reaching undetectable levels at age 29 days
Plasma HIV RNA remained undetectable between months 1 through 26, despite discontinuation of ART at age 18 months
![Page 7: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/7.jpg)
A “functional cure”
Ultrasensitive methods found a single copy of HIV RNA in plasma at age 24 months
Replication-competent virus was not detected following co-culture of 22 million purified resting CD4+ T cells
Plasma viral load, PBMC DNA, and HIV-specific antibodies remained undetectable with standard clinical assays
![Page 8: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/8.jpg)
Why did this approach work?
![Page 9: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/9.jpg)
What about the first patient cured of HIV infection?
![Page 10: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/10.jpg)
![Page 11: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/11.jpg)
New approaches to treatment: Targeting the CCR5 Receptor
![Page 12: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/12.jpg)
HIV binds to the CCR5 receptor to enter immune cells
![Page 13: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/13.jpg)
![Page 14: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/14.jpg)
![Page 15: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/15.jpg)
“When to start treatment?”
New recommendations
![Page 16: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/16.jpg)
Understanding the alphabet soup of recommendations
![Page 17: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/17.jpg)
When to start: Overall
![Page 18: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/18.jpg)
What are the reasons for this new recommendation? Benefit to the patient
AIDS defining events Cancers All cause mortality
Benefit to the patient’s partner ART was 96% effective in reducing
transmission between discordant couples
![Page 19: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/19.jpg)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
![Page 20: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/20.jpg)
When to start: Specific conditions
![Page 21: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/21.jpg)
When to start: Opportunistic infections
![Page 22: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/22.jpg)
A new one-pill-once-daily regimen
![Page 23: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/23.jpg)
![Page 24: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/24.jpg)
Percentage of patients with undetectable viral loads
![Page 25: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/25.jpg)
Mean change of CD4 from baseline
![Page 26: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/26.jpg)
Change in kidney function
![Page 27: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/27.jpg)
![Page 28: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/28.jpg)
A new indication for antiretroviral therapy
![Page 29: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/29.jpg)
![Page 30: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/30.jpg)
![Page 31: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/31.jpg)
Take home message
![Page 32: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/32.jpg)
From 2 years ago...
![Page 33: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/33.jpg)
![Page 34: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/34.jpg)
Why not 100% protection? Adherence
![Page 35: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/35.jpg)
http://www.cdc.gov/hiv/prep/
![Page 36: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/36.jpg)
What is a REMS?
Risk Evaluation and Mitigation Strategy
Manage known or potential serious risks with a drug or biological product
FDA sometimes determines that a REMS is needed in order for the benefits to outweigh the risks of an approved drug
REMS may include: Medication Guide, Patient Package Insert, communication plan, and other elements to assure safe use
![Page 37: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/37.jpg)
https://www.truvadapreprems.com/#
![Page 38: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/38.jpg)
New treatments (and new drug-drug interactions) for hepatitis C co-infection
![Page 39: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/39.jpg)
![Page 40: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/40.jpg)
HIV and Hepatitis C
~30% if HIV-infected individuals in the U.S. are co-infected with hepatitis C
Chronic hepatitis C infection is a leading cause of liver disease and mortality in HIV-infected patients
HIV/hepatitis C co-infected patients are at greater risk for liver disease and death, compared with hepatitis C patients without HIV infection
![Page 41: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/41.jpg)
Improved sustained virologic response with the new treatments in HIV/hepatitis C co-infected patients
Telaprevir + PegIFN/Ribavirin
PegIFN/Ribavirin
Boceprevir + PegIFN/Ribavirin
PegIFN/Ribavirin
![Page 42: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/42.jpg)
Beware drug-drug interactions!
![Page 43: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/43.jpg)
For now, three options
Telaprevir NRTI backbone plus either raltegravir,
efavirenz, atazanavir/ritonavir, etravirine, or riplivirine
With efavirenz, increase dose of telaprevir
Boceprevir NRTI backbone plus raltegravir
Wait... New treatments on the horizon for 2014
![Page 44: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/44.jpg)
So what’s new in 2013?
New report of a cured patient New research towards a “functional cure” New guidelines for “when to start” therapy
in different patient populations New one-pill-once-daily treatment regimen New indication for antiretroviral therapy
Pre-exposure prophylaxis New hepatitis C treatments, and new drug-
drug interactions with antiretroviral therapy
![Page 45: Dr. Chris Vinnard's 2013 HIV Treatment Update](https://reader035.vdocument.in/reader035/viewer/2022070601/588a659f1a28ab7a768b736f/html5/thumbnails/45.jpg)
Newest member of the Vinnard family
Thank you!